Key Takeaways
- First-quarter revenue reached $15.29B, surpassing the $14.94B consensus projection
- Core earnings per share of $2.58 exceeded analyst expectations of $2.54
- Oncology division reported 16% year-over-year growth; rare disease segment increased 15%
- Company reaffirmed full-year outlook: mid-to-high single-digit revenue expansion, low double-digit core EPS advancement
- Shares declined approximately 1% following results, with market watchers noting the positive momentum had been anticipated
AstraZeneca launched Wednesday’s trading session with impressive quarterly figures, yet investors responded with indifference. The British pharmaceutical giant reported first-quarter revenue totaling $15.29 billion, representing an increase from $13.59 billion in the prior-year period and exceeding the $14.94 billion Wall Street consensus.
Earnings per share on a core basis registered at $2.58, topping the anticipated $2.54 figure. Core operating profit expanded 12% to reach $4.25 billion.
Despite outperforming expectations, AZN shares dropped roughly 1% during early London market hours. Adam Vettese, an analyst with eToro, characterized the market response as “muted” since the company’s positive trajectory had already been factored into valuations.
The oncology portfolio continues to serve as the primary growth driver, representing 44% of total group revenue. The division’s sales climbed 16% year-over-year on a constant currency basis to $6.8 billion.
Imfinzi, utilized for bladder and lung cancer treatment, experienced a 30% surge to $1.7 billion. Tagrisso, a lung cancer medication, increased 5% to $1.8 billion. Enhertu, targeting breast and gastric malignancies, soared 34% to $831 million.
The rare disease business unit similarly performed strongly, posting a 15% annual increase in sales.
Oncology and Rare Disease Portfolios Power Growth
Revenue from the United States expanded 10% during the quarter, while Chinese market sales advanced 2%. AstraZeneca has executed significant strategic initiatives in both territories throughout the previous year, including a $50 billion U.S. manufacturing arrangement and a $15 billion investment pledge in China.
The pharmaceutical company also obtained an NYSE listing and received exemption from U.S. tariffs through a drug pricing accord.
Net income for the first quarter climbed to $3.08 billion compared to $2.92 billion in the same period last year.
Product Pipeline and 2030 Ambitions Remain Intact
Chief Executive Pascal Soriot reinforced the organization’s $80 billion annual revenue objective for 2030. He indicated that AstraZeneca is positioning itself for numerous product introductions and maintains its trajectory to achieve more than 20 new launches by that timeframe.
Three novel medications could receive U.S. market authorization this year subject to regulatory clearance: baxdrostat for hypertension management, camizestrant for a specific breast cancer type, and gefurulimab for a chronic autoimmune condition.
The full-year 2026 forecast remained unaltered. AstraZeneca anticipates mid-to-high single-digit revenue progression and low double-digit core EPS expansion at constant currency rates.
Soriot cautioned last week that Europe faces the prospect of becoming merely a “sales office” for the pharmaceutical sector as it lags behind the United States and China. This perspective underlies AstraZeneca’s ongoing efforts to strengthen its presence in both markets.
LSEG analysts project full-year 2026 sales growth of 7.2% and profit expansion of 11.2%, generally consistent with 2025 performance.
AstraZeneca’s shares have remained essentially unchanged year-to-date prior to today’s earnings announcement. The better-than-expected results did little to alter that trajectory.
